A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis

• Published in: Journal of neurology Vol. 270; no. 9; pp. 4403 - 4414
• Main Authors: Louapre, C., Rosenzwajg, M., Golse, M., Roux, A., Pitoiset, F., Adda, L., Tchitchek, N., Papeix, C., Maillart, E., Ungureanu, A., Charbonnier-Beaupel, F., Galanaud, D., Corvol, J. C., Vicaut, E., Lubetzki, C., Klatzmann, D.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2023; Springer Nature B.V; Springer Verlag
• Subjects: Adult; Amyotrophic lateral sclerosis; Autoimmune diseases; CD25 antigen; Clinical trials; Cytokines; Double-Blind Method; Double-blind studies; Effector cells; Female; Humans; Immunological diseases; Immunology; Immunoregulation; Interleukin 2; Interleukin-2 - therapeutic use; Life Sciences; Lymphocytes T; Male; Medicine; Medicine & Public Health; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Myelination; NCT; NCT02424396; Neurology; Neuroradiology; Neurosciences; Original Communication; Patients; Phenotypes; Placebos; Treatment Outcome; Tolerance; Neuroinflammation; Immunosuppression; Neurodegeneration; Immunoregulation; Immunotherapy; NCT02424396; EU Clinical trials Register: 2014-000088-42 Neuroinflammation; EU Clinical trials Register: 2014-000088-42 Neuroinflammation Neurodegeneration Immunoregulation Immunosuppression Tolerance Immunotherapy

Background Multiple sclerosis (MS) is associated with regulatory T cells (Tregs) insufficiency while low-dose interleukin-2 (IL2 LD ) activates Tregs and reduces disease activity in autoimmune diseases. Methods We aimed at addressing whether IL2 LD improved Tregs from MS patients. MS-IL2 was a singl...